Clinical trials: Young Population
Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
- Trial name
- NCT07616934
- Testing
- VAX-A1 Low, VAX-A1 Mid, VAX-A1 High
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
Safety and Tolerability of Lu AG06474 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AG06474 and what the body does to Lu AG06474 after swallowing single doses of the drug.
- Trial name
- NCT05003687
- Testing
- Lu AG06474
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose to Japanese healthy subjects.
- Trial name
- NCT00972049
- Testing
- AZD2516
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dravet Syndrome
A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet…
- Trial name
- NCT02926898
- Testing
- ZX008 (Fenfluramine Hydrochloride)
- Where
- 28 sites in United States, Canada and 5 more
- Volunteers
- 87 people
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Parkinson Disease
Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects
the purpose of the study was to the compare pharmacokinetic profile of BIA 6-512 in healthy elderly subjects versus healthy young subjects after single and repeated oral administration of 200 mg BIA 6-512.
- Trial name
- NCT03095105
- Testing
- 200 mg BIA 6-512
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pain
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
The purpose of this study is to investigate the safety and tolerability of AZD2066 using multiple escalating dose panels. There will be separate panels for young healthy volunteers and elderly healthy volunteers.
- Trial name
- NCT00684502
- Testing
- AZD2066
- Where
- Sweden
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Infections, Meningococcal
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY)…
- Trial name
- NCT04502693
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), MenABCWY-1
- Where
- 112 sites in United States, Australia and 5 more
- Volunteers
- 3,657 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers
Three-part study investigating the safety and tolerability of AZD2423 multiple doses in 98 healthy volunteers: Part 1 80 young and elderly subjects in a parallel, double blind, randomised study.
- Trial name
- NCT00977626
- Testing
- Part 2 - AZD2423, Part 3 - AZD2423
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers
The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose.
- Trial name
- NCT00754715
- Testing
- AZD2516
- Where
- Sweden
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Safety and Tolerability of Lu AG06479 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.
- Trial name
- NCT04473651
- Testing
- Lu AG06479
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Safety and Tolerability of Lu AF95245 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and what the body does to Lu AF95245 after swallowing single doses of the drug
- Trial name
- NCT04199585
- Testing
- Lu AF95245, Lu AF95245 14C radiolabelled spiked dosage
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD2423 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01233830
- Testing
- AZD2423
- Where
- Japan
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Influenza
Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)
The purpose of this Phase II follow-up study (to study 810501) is to assess the immunogenicity and safety of a booster vaccination with a non-adjuvanted H5N1 influenza vaccine administered 12 to 17 months after a two-dose regimen…
- Trial name
- NCT00530660
- Testing
- H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted
- Where
- Austria
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Healthy
A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.
- Trial name
- NCT04537897
- Testing
- BI 474121, Midazolam
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men
This study evaluates the effect of Lu AF88434 on the body and what the body does to Lu AF88434 and the effect of food after swallowing single oral doses
- Trial name
- NCT04082325
- Testing
- Lu AF88434, Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434), Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
- Where
- Netherlands
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Infection by Human Papilloma Virus
Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise
Human papillomavirus (HPV) infection is the most common sexually transmitted infection. The high risk oncogenic types, HPV-16 and -18 are responsible for 70% of cervical cancers.
- Trial name
- DyPAVIR (NCT01988948)
- Testing
- Various biological sampling
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Healthy
Single Ascending Dose Study of Lu AF76432 in Healthy Young Men
The purpose of this study is to investigate safety, tolerability and pharmacokinetics of the drug Lu AF76432 given as single oral ascending doses to healthy young men
- Trial name
- NCT03531229
- Testing
- Lu AF76432
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers
The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers.
- Trial name
- NCT01161069
- Testing
- PF-03049423
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Group B Streptococcal Disease
Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China
Evaluate the burden of invasive group B streptococcal (GBS) disease in young infants (up to 90 days of age) in China, in terms of incidence, case fatality rate and serotype distribution
- Trial name
- NCT01933646
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Novartis Vaccines